Uno studio del primo uomo per imparare come è Safe Bay 3713372 e come funziona nei partecipanti con tumori solidi de-difensori MTAP
Uno studio del primo umano per valutare la sicurezza, la tollerabilità e la farmacocinetica, la farmacodinamica e l'attività clinica preliminare della baia 3713372, un nuovo inibitore PRMT5 di seconda generazione, nei partecipanti con tumori solidi de-slitti di MTAP.
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells.
The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors.
For this, the researchers will study and analyze:
- the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity.
- the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose.
- the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses.
- the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses.
Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse.
The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase.
Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems.
Participants will visit the study site:
- at least twice before the treatment starts
- multiple times when they start taking the treatment
- once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason
During the study, the doctors and their study team will:
- check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram
- check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan
- take tumor samples
The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Bayer Clinical Trials Contact
- Numero di telefono: 18888422937
- Email: clinical-trials-contact@bayer.com
Luoghi di studio
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Reclutamento
- Chris O'Brien Lifehouse
-
Concord, New South Wales, Australia, 2139
- Reclutamento
- Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre
-
Epping, New South Wales, Australia, 3076
- Non ancora reclutamento
- Northern Hospital
-
Waratah, New South Wales, Australia, 2298
- Reclutamento
- Calvary Mater Hospital Newcastle - Oncology
-
-
-
-
Antwerp
-
Antwerp, Antwerp, Belgio, 2650
- Reclutamento
- Antwerp University Hospital | Oncology Department
-
-
East Flanders
-
Ghent, East Flanders, Belgio, 9000
- Reclutamento
- Ghent University Hospital | Drug Research Unit Department
-
-
Flemish Brabant
-
Leuven, Flemish Brabant, Belgio, 3000
- Reclutamento
- UZ Leuven Gasthuisberg - Pneumology Department
-
-
Liège
-
Liège, Liège, Belgio, 4000
- Reclutamento
- Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology
-
-
-
-
Olomouc Region
-
Olomouc, Olomouc Region, Cechia, 779 00
- Reclutamento
- Fakultní nemocnice Olomouc - Onkologická klinika
-
-
South Moravian
-
Brno, South Moravian, Cechia, 602 00
- Reclutamento
- Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 100142
- Reclutamento
- Beijing Cancer Hospital - Oncology Department
-
Beijing, Beijing Municipality, Cina, 101149
- Non ancora reclutamento
- Beijing chest hospital, Capital Medical University
-
-
Hubei
-
Wuhan, Hubei, Cina, 430075
- Reclutamento
- Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
-
-
Jiangsu
-
Nanjing, Jiangsu, Cina, 210029
- Non ancora reclutamento
- Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Cina, 310016
- Non ancora reclutamento
- Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
-
-
-
-
Capital Region / Region Hovedstaden
-
Copenhagen, Capital Region / Region Hovedstaden, Danimarca, 2100
- Reclutamento
- Rigshospitalet Copenhagen University Hospital | Oncology Department
-
-
Region of Southern Denmark / Region Syddanmark
-
Odense, Region of Southern Denmark / Region Syddanmark, Danimarca, 5000
- Reclutamento
- Odense University Hospital | Svendborg Sygehus - Oncology Department
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 466-8560
- Non ancora reclutamento
- Nagoya University Hospital
-
-
Osaka
-
Sakai, Osaka, Giappone, 590-0197
- Reclutamento
- Kindai University Hospital
-
-
Shizuoka
-
Sunto, Shizuoka, Giappone, 411-8777
- Reclutamento
- Shizuoka Cancer Center
-
-
Tokyo
-
Chuo-ku, Tokyo, Giappone, 104-0045
- Reclutamento
- National Cancer Center Hospital
-
Koto-ku, Tokyo, Giappone, 135-8550
- Reclutamento
- The Cancer Institute Hospital of JFCR
-
-
-
-
Friuli Venezia Giulia
-
Aviano, Friuli Venezia Giulia, Italia, 33081
- Reclutamento
- Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati
-
-
Lazio
-
Rome, Lazio, Italia, 00128
- Reclutamento
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
-
Rome, Lazio, Italia, 00144
- Non ancora reclutamento
- I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione
-
-
Lombardy
-
Milan, Lombardy, Italia, 20133
- Reclutamento
- Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
-
Rozzano, Lombardy, Italia, 20089
- Reclutamento
- Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
-
-
-
-
North Holland
-
Amsterdam, North Holland, Olanda, 1066 CX
- Reclutamento
- Nederlands Kanker Instituut
-
-
Provincie Groningen
-
Groningen, Provincie Groningen, Olanda, 9713 GZ
- Non ancora reclutamento
- Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center
-
-
South Holland
-
Rotterdam, South Holland, Olanda, 3015 CE
- Reclutamento
- Erasmus Medisch Centrum
-
-
-
-
Greater Manchester
-
Manchester, Greater Manchester, Regno Unito, M20 4BX
- Reclutamento
- The Christie Hospital | Experimental Cancer Medicine Team
-
-
Surrey
-
Sutton, Surrey, Regno Unito, SM2 5PT
- Non ancora reclutamento
- The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit
-
-
-
-
Singapore
-
Singapore, Singapore, Singapore, 119074
- Reclutamento
- National University Hospital Medical Centre
-
Singapore, Singapore, Singapore, 168583
- Reclutamento
- National Cancer Center Singapore - Oncology Department
-
Singapore, Singapore, Singapore, 217562
- Reclutamento
- Icon Cancer Centre
-
-
-
-
Barcelona
-
Barcelona, Barcelona, Spagna, 08023
- Reclutamento
- Hospital Hm Nou Delfos | Oncologia
-
Barcelona, Barcelona, Spagna, 08035
- Reclutamento
- Hospital Universitari Vall D Hebron | Oncologia
-
-
Chartered Community of Navarre
-
Pamplona, Chartered Community of Navarre, Spagna, 31008
- Reclutamento
- Clinica Universidad De Navarra | Pamplona | Oncologia
-
-
La Rioja
-
Logroño, La Rioja, Spagna, 26006
- Reclutamento
- Hospital San Pedro | Oncologia
-
-
Madrid
-
Madrid, Madrid, Spagna, 28040
- Reclutamento
- Hospital Universitario Fundacion Jimenez Diaz | Oncologia
-
Pozuelo de Alarcón, Madrid, Spagna, 28223
- Reclutamento
- NEXT - Hospital Universitario Quironsalud Madrid | Oncologia
-
-
Málaga
-
Málaga, Málaga, Spagna, 29010
- Reclutamento
- Hospital Universitario Virgen De La Victoria | Oncologia
-
-
Valencia
-
Valencia, Valencia, Spagna, 46010
- Non ancora reclutamento
- Hospital Clinico Universitario De Valencia | Oncologia
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35233
- Non ancora reclutamento
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital
-
-
California
-
Duarte, California, Stati Uniti, 91010
- Non ancora reclutamento
- City of Hope - Duarte Cancer Center
-
Los Angeles, California, Stati Uniti, 90095
- Non ancora reclutamento
- UCLA Health Bowyer Oncology Center
-
San Francisco, California, Stati Uniti, 94143
- Reclutamento
- UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
-
Stanford, California, Stati Uniti, 94305
- Non ancora reclutamento
- Stanford University Medical Center - Neurology
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Non ancora reclutamento
- UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
-
Denver, Colorado, Stati Uniti, 80218
- Reclutamento
- Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
-
-
Florida
-
Orlando, Florida, Stati Uniti, 32827
- Reclutamento
- Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Non ancora reclutamento
- Dana-Farber Cancer Institute - Oncology Department
-
Boston, Massachusetts, Stati Uniti, 02114
- Reclutamento
- Massachusetts General Hospital - Neurology
-
-
Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49546
- Reclutamento
- START | Midwest
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Memorial Sloan Kettering Cancer Center New York - Main Campus
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Icahn School of Medicine at Mount Sinai - Oncology
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- SCRI Oncology Partners
-
-
Texas
-
Irving, Texas, Stati Uniti, 75039
- Reclutamento
- NEXT Dallas - Oncology Department
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- START | San Antonio
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Non ancora reclutamento
- Froedtert Hospital - Clinical Cancer Center
-
-
-
-
Stockholm County
-
Stockholm, Stockholm County, Svezia, 171 76
- Reclutamento
- Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC
-
-
Västra Götaland County
-
Gothenburg, Västra Götaland County, Svezia, 413 46
- Non ancora reclutamento
- Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Participant must be ≥ 18 years old of age, or the legal age of consent in the jurisdiction of the country in which the study takes place, at the time of signing the informed consent.
- At least one measurable lesion that would qualify as target lesion by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).
- Homozygous MTAP-deletion identified through molecular testing from a locally certified laboratory.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
-
Previous additional cancer other than the one evaluated in this study within the past 2 years except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study.
-
A marked prolongation of QT/QTc interval at screening (e.g., repeated demonstration of a QTc interval >450 ms). Participants with permanent pacemakers (i.e., a paced rhythm) may be eligible based on the investigator's clinical assessment and discretion.
-
Cardiac history comprising:
- History of congestive heart failure Class >II according to the New York Heart Association Functional Classification.
- Myocardial infarction less than 6 months before the start of study intervention.
- Serious cardiac arrhythmias requiring treatment or any clinically important abnormalities in rhythm, conduction or morphology on resting ECG with the exception of atrial fibrillation which is well-controlled and requires only digoxin or beta blockers.
-
Unstable angina within 4 weeks before start of study intervention.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Dose Escalation (Intervention Cohort 1)
For the escalation part, different dose levels of BAY 3713372 administered as monotherapy are planned. |
Daily oral administration |
|
Sperimentale: Backfill cohorts in Intervention Cohort 1 (Dose Escalation)
Backfill cohorts may be initiated concurrently with dose escalation cohorts to generate additional safety, pharmacokinetic, and pharmacodynamic data to facilitate the selection of the optimal doses for use in further development. |
Daily oral administration |
|
Sperimentale: Dose Expansion (Intervention Cohort 1)
Dose expansion with BAY 3713372 monotherapy in selected participants with MTAP-deleted solid tumors. |
Daily oral administration |
|
Sperimentale: Dose Expansion (Intervention Cohort 2)
Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted non-small cell lung cancer (NSCLC). |
Daily oral administration |
|
Sperimentale: Dose Expansion (Intervention Cohort 3)
Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC. |
Daily oral administration |
|
Sperimentale: Dose Expansion (Intervention Cohort 4)
Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC. |
Daily oral administration |
|
Sperimentale: Dose Expansion (Intervention Cohort 5)
Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC). |
Daily oral administration |
|
Sperimentale: Dose Expansion (Intervention Cohort 6)
Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted PDAC. |
Daily oral administration |
|
Sperimentale: Window-of-opportunity trial in participants with MTAP-deleted GBM (Intervention Cohort 7)
A surgical window-of-opportunity trial of BAY 3713372 alone in participants with MTAP-deleted glioblastoma (GBM). |
Daily oral administration |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Escalation della dose (coorte master e di intervento 1): concentrazione massima (CMAX) del rispettivo intervallo di dosaggio della baia 3713372
Lasso di tempo: Dalla prima dose di intervento di studio fino al ciclo 2 giorni 1 (ogni ciclo è di 21 giorni)
|
Dalla prima dose di intervento di studio fino al ciclo 2 giorni 1 (ogni ciclo è di 21 giorni)
|
|
|
Escalation della dose (coorte master e di intervento 1): area sotto la curva (AUC) del rispettivo intervallo di dosaggio della baia 3713372
Lasso di tempo: Dalla prima dose di intervento di studio fino al ciclo 2 giorni 1 (ogni ciclo è di 21 giorni)
|
Dalla prima dose di intervento di studio fino al ciclo 2 giorni 1 (ogni ciclo è di 21 giorni)
|
|
|
Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent adverse events (TEAEs)
Lasso di tempo: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent serious adverse events (TESAEs)
Lasso di tempo: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Escalation (Master and Intervention Cohort 1): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Lasso di tempo: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Escalation (Master and Intervention Cohort 1): Incidence of dose-limiting toxicities (DLTs)
Lasso di tempo: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0 |
From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
|
Dose Escalation (Master and Intervention Cohort 1): Number of participants with DLTs
Lasso di tempo: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
Number of participants with at least one DLT |
From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Objective response rate (ORR)
Lasso di tempo: Approximately 1.5 years
|
Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) |
Approximately 1.5 years
|
|
Dose Expansion (Intervention Cohorts 3, 4 and 6): Number of participants with DLTs
Lasso di tempo: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
|
Number of participants with at least one DLT |
From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
|
|
Intervention Cohort 7: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Lasso di tempo: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Intervention Cohort 7: Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Lasso di tempo: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Intervention Cohort 7: Number of participants with DLTs
Lasso di tempo: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
Number of participants with at least one DLT |
From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)
|
|
Intervention Cohort 7: Brain and brain tumor PK concentration of BAY 3713372
Lasso di tempo: From first dose through day of surgery (approximately 7 ± 2 days)
|
Concentration of BAY 3713372 in enhancing and non-enhancing brain tumor tissue obtained at definitive surgery, with corresponding time-matched plasma concentrations and estimation of tumor-to-plasma exposure ratios |
From first dose through day of surgery (approximately 7 ± 2 days)
|
|
Intervention Cohort 7: Tumor tissue SDMA levels
Lasso di tempo: From first dose through day of surgery (approximately 7 ± 2 days)
|
Change in symmetric dimethylarginine (SDMA) levels in brain tumor tissue collected at definitive surgery following neoadjuvant BAY 3713372 treatment, as a pharmacodynamic marker of PRMT5 inhibition |
From first dose through day of surgery (approximately 7 ± 2 days)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Escalation della dose (coorte master e di intervento 1): tempo di risposta (TTR)
Lasso di tempo: Circa 1,5 anni
|
Circa 1,5 anni
|
|
|
Espansione della dose (Master, Coorti di intervento 1 - 6): Time to Response (TTR)
Lasso di tempo: Circa 1,5 anni
|
Circa 1,5 anni
|
|
|
Espansione della dose (coorte di intervento 1 - 4 e 6): concentrazione massima (CMAX) del rispettivo intervallo di dosaggio della baia 3713372
Lasso di tempo: Dalla prima dose di intervento di studio fino al ciclo 2 giorni 1 (ogni ciclo è di 21 giorni, ad eccezione della coorte di intervento 6, che ha una durata del ciclo di 28 giorni)
|
Dalla prima dose di intervento di studio fino al ciclo 2 giorni 1 (ogni ciclo è di 21 giorni, ad eccezione della coorte di intervento 6, che ha una durata del ciclo di 28 giorni)
|
|
|
Espansione della dose (coorte di intervento 1 - 4 e 6): area sotto la curva (AUC) del rispettivo intervallo di dosaggio della baia 3713372
Lasso di tempo: Dalla prima dose di intervento di studio fino al ciclo 2 giorni 1 (ogni ciclo è di 21 giorni, ad eccezione della coorte di intervento 6, che ha una durata del ciclo di 28 giorni)
|
Dalla prima dose di intervento di studio fino al ciclo 2 giorni 1 (ogni ciclo è di 21 giorni, ad eccezione della coorte di intervento 6, che ha una durata del ciclo di 28 giorni)
|
|
|
Dose Expansion (Part A of Intenvention Cohort 2): Time to CNS progression (CNS-TTP)
Lasso di tempo: Approximately 3 years
|
Approximately 3 years
|
|
|
Dose Expansion (Part B of Intervention Cohort 2): CNS-related disease control rate (CNS-DCR) in active brain metastases
Lasso di tempo: Approximately 1.5 years
|
Approximately 1.5 years
|
|
|
Dose Escalation (Master and Intervention Cohort 1): Objective response rate (ORR)
Lasso di tempo: Approximately 1.5 years
|
Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) |
Approximately 1.5 years
|
|
Dose Escalation (Master and Intervention Cohort 1): Duration of response (DOR)
Lasso di tempo: Approximately 3 years
|
Determined by the investigator according to RECIST v1.1 |
Approximately 3 years
|
|
Dose Escalation (Master and Intervention Cohort 1): Progression-free survival (PFS)
Lasso di tempo: Approximately 3 years
|
Determined by the investigator according to RECIST v1.1 |
Approximately 3 years
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent adverse events (TEAEs)
Lasso di tempo: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent serious adverse events (TESAEs)
Lasso di tempo: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
Lasso di tempo: From the first administration of study intervention up to 30 days after the last dose of study intervention
|
TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary |
From the first administration of study intervention up to 30 days after the last dose of study intervention
|
|
Dose Expansion (Master, Intervention Cohorts 1, 3, 4, and 6): Incidence of dose-limiting toxicities (DLTs)
Lasso di tempo: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
|
DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0 |
From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Duration of response (DOR)
Lasso di tempo: Approximately 3 years
|
Determined by the investigator according to RECIST v1.1 |
Approximately 3 years
|
|
Dose Expansion (Master, Intervention Cohorts 1 - 6): Progression-free survival (PFS)
Lasso di tempo: Approximately 3 years
|
Determined by the investigator according to RECIST v1.1 |
Approximately 3 years
|
|
Dose Expansion (Part B of Intervention Cohort 2): CNS-ORR for active brain metastases
Lasso di tempo: Approximately 1.5 years
|
CNS-ORR: CNS objective response rate |
Approximately 1.5 years
|
|
Dose Expansion (Part B of Intervention Cohort 2): CNS-DOR for active brain metastases
Lasso di tempo: Approximately 3 years
|
CNS-DOR: Duration of CNS response |
Approximately 3 years
|
|
Dose Expansion (Part B of Intervention Cohort 2): CNS-PFS for active brain metastases
Lasso di tempo: Approximately 3 years
|
CNS-PFS: Survival without CNS progression |
Approximately 3 years
|
|
Dose Expansion (Part B of Intervention Cohort 2): CNS-TTR for active brain metastases
Lasso di tempo: Approximately 1.5 years
|
CNS-TTR: Time to CNS response |
Approximately 1.5 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Malattie polmonari
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Neoplasie polmonari
- Astrocitoma
- Glioma
- Neoplasie, Neuroepiteliali
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Glioblastoma
- Carcinoma, polmone non a piccole cellule
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 22931
- 2025-520623-24-00 (Identificatore di registro: CTIS (EU))
- 2025 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .